Back
Day Range
$201.80
$206.01
52-Week Range
$164.39
$244.81
Volume
6,972,423
50D / 200D Avg
$223.12
/
$215.25
Prev Close
$204.93
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (627 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 85.8 | 0.3 |
| P/B | — | 2.9 |
| ROE % | 15367.3 | 3.7 |
| Net Margin % | 6.9 | 3.8 |
| Rev Growth 5Y % | 2.1 | 10.0 |
| D/E | — | 0.2 |
Analyst Price Target
Hold
$256.15
+24.9%
Low: $223.00
High: $299.00
Forward P/E
14.1
Forward EPS
$14.57
EPS Growth (est.)
+0.0%
Est. Revenue
67 B
Earnings Estimates
| Period | EPS Est. | Revenue Est. | Analysts |
|---|---|---|---|
| FY2030 |
$20.05
$19.56 – $20.40
|
84 B | 5 |
| FY2029 |
$19.55
$19.07 – $19.89
|
82 B | 10 |
| FY2028 |
$17.87
$13.13 – $21.13
|
78 B | 12 |
Insider Trading Activity
20 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 27, 2026 |
Michael Robert A.
CHAIRMAN OF THE BOARD AND CEO
|
other | 36,523 | $232.08 | $8,476,258 |
| Feb 27, 2026 |
Reents Scott T
EVP, CHIEF FINANCIAL OFFICER
|
other | 21,638 | $232.08 | $5,021,747 |
| Feb 27, 2026 |
Donoghoe Nicholas
EVP, CHIEF BUS/STRAT OFFICER
|
other | 12,874 | $232.08 | $2,987,798 |
| Feb 27, 2026 |
Purdue David Ryan
SVP, Controller
|
other | 2,692 | $232.08 | $624,759 |
| Feb 27, 2026 |
Thakkar Roopal
EVP, R&D and CSO
|
other | 8,037 | $232.08 | $1,865,227 |
| Feb 27, 2026 |
SALEKI-GERHARDT AZITA
EVP, CHIEF OPERATIONS OFFICER
|
other | 16,309 | $232.08 | $3,784,993 |
| Dec 31, 2025 |
Quaggin Susan E
|
grant | 68 | $228.49 | $15,537 |
| Sep 30, 2025 |
RAPP EDWARD J
|
grant | 145 | $231.54 | $33,573 |
| Sep 30, 2025 |
Quaggin Susan E
|
grant | 67 | $231.54 | $15,513 |
| Jun 30, 2025 |
Quaggin Susan E
|
grant | 81 | $185.62 | $15,035 |
| Jun 30, 2025 |
Alpern Robert J
|
grant | 40 | $185.62 | $7,425 |
| May 9, 2025 |
Davis Jennifer L.
|
grant | 1,203 | — | — |
| May 9, 2025 |
Alpern Robert J
|
grant | 1,203 | — | — |
| May 9, 2025 |
Quaggin Susan E
|
grant | 1,203 | — | — |
| May 9, 2025 |
Hart Brett J
|
grant | 1,203 | — | — |
| May 9, 2025 |
AUSTIN ROXANNE S
|
grant | 1,203 | — | — |
| May 9, 2025 |
RAPP EDWARD J
|
grant | 1,203 | — | — |
| May 9, 2025 |
WADDELL FREDERICK H
|
grant | 1,203 | — | — |
| Mar 31, 2025 |
GONZALEZ RICHARD A
|
other | 2,450 | — | — |
| Mar 31, 2025 |
RAPP EDWARD J
|
grant | 155 | $209.52 | $32,476 |
Key Takeaways
Revenue grew 2.14% annually over 5 years — modest growth
ROE of 15367.27% indicates high profitability
Generating 17.82B in free cash flow
P/E of 85.82 — premium valuation
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 6.43%
Cash machine — converts 421.58% of earnings into free cash flow
Growth
Revenue Growth (5Y)
2.14%
Revenue (1Y)8.57%
Earnings (1Y)-1.22%
FCF Growth (3Y)-10.14%
Quality
Return on Equity
15367.27%
ROIC24.18%
Net Margin6.91%
Op. Margin34.69%
Safety
Debt / Equity
N/A
Current Ratio0.67
Interest Coverage8.08
Valuation
P/E Ratio
85.82
P/B RatioN/A
EV/EBITDA20.11
Dividend Yield0.03%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 8.57% | Revenue Growth (3Y) | 6.11% |
| Earnings Growth (1Y) | -1.22% | Earnings Growth (3Y) | -6.78% |
| Revenue Growth (5Y) | 2.14% | Earnings Growth (5Y) | -22.21% |
| Profitability | |||
| Revenue (TTM) | 61.16B | Net Income (TTM) | 4.23B |
| ROE | 15367.27% | ROA | 3.15% |
| Gross Margin | 83.71% | Operating Margin | 34.69% |
| Net Margin | 6.91% | Free Cash Flow (TTM) | 17.82B |
| ROIC | 24.18% | FCF Growth (3Y) | -10.14% |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 0.67 |
| Interest Coverage | 8.08 | Dividend Yield | 0.03% |
| Valuation | |||
| P/E Ratio | 85.82 | P/B Ratio | N/A |
| P/S Ratio | 5.93 | PEG Ratio | -116.18 |
| EV/EBITDA | 20.11 | Dividend Yield | 0.03% |
| Market Cap | 362.69B | Enterprise Value | 426.53B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 61.16B | 56.33B | 54.32B | 58.05B | 56.20B |
| Net Income | 4.23B | 4.28B | 4.86B | 11.84B | 11.54B |
| EPS (Diluted) | 2.36 | 2.39 | 2.72 | 6.63 | 6.45 |
| Gross Profit | 51.20B | 39.43B | 33.90B | 40.64B | 38.75B |
| Operating Income | 21.21B | 9.14B | 12.76B | 18.12B | 17.92B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 133.96B | 135.16B | 134.71B | 138.81B | 146.53B |
| Total Liabilities | 137.19B | 131.80B | 124.31B | 121.52B | 131.09B |
| Shareholders' Equity | -3.27B | 3.33B | 10.36B | 17.25B | 15.41B |
| Total Debt | 69.07B | 67.84B | 60.12B | 64.19B | 77.58B |
| Cash & Equivalents | 5.23B | 5.52B | 12.81B | 9.20B | 9.75B |
| Current Assets | 29.06B | 25.58B | 33.00B | 28.46B | 27.93B |
| Current Liabilities | 43.29B | 38.75B | 37.84B | 29.54B | 35.19B |